Ardelyx (ARDX) Change in Accured Expenses (2013 - 2026)
Ardelyx (ARDX) reported Change in Accured Expenses of $19.0 million for Q1 2026, up 344.75% on a YoY basis from $4.3 million in Q1 2025, and up 681.51% quarter-over-quarter from $2.4 million in Q4 2025.
Ardelyx (ARDX) Change in Accured Expenses (2013 - 2026) Analysis & Trends
Ardelyx has reported Change in Accured Expenses for 14 years, with the latest figure at $19.0 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Accured Expenses rose 344.75% year-over-year to $19.0 million; the trailing twelve-month figure through Mar 2026 stood at $41.3 million (up 113.62% YoY), and the FY2025 full-year result was $14.5 million, down 31.57% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at $19.0 million, up from $2.4 million in the prior quarter.
- The five-year high for Change in Accured Expenses was $19.0 million in Q1 2026, with the low at -$7.8 million in Q1 2025.
- Historically, Change in Accured Expenses has averaged $3.8 million across 5 years, with a median of $2.0 million in 2022.
- The largest YoY upside for Change in Accured Expenses was 1083.07% in 2024 against a maximum downside of 320.49% in 2024.
- Ardelyx's Change in Accured Expenses stood at $2.4 million in 2022, then jumped by 77.04% to $4.2 million in 2023, then sank by 63.23% to $1.6 million in 2024, then jumped by 56.13% to $2.4 million in 2025, then soared by 681.51% to $19.0 million in 2026.
- The last three Change in Accured Expenses figures came in at $19.0 million (Q1 2026), $2.4 million (Q4 2025), and $4.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 931,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ardelyx | 1.49 Bn | 1.25 Bn | 89.66 Mn | 19.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.02 Mn |
| Mar 31, 2026 | 19.02 Mn |
| Dec 31, 2025 | 2.43 Mn |
| Dec 31, 2025 | 2.43 Mn |
| Sep 30, 2025 | 4.63 Mn |
| Sep 30, 2025 | 4.63 Mn |
| Jun 30, 2025 | 15.25 Mn |
| Jun 30, 2025 | 15.25 Mn |
| Mar 31, 2025 | -7.77 Mn |
| Mar 31, 2025 | -7.77 Mn |
| Dec 31, 2024 | 1.56 Mn |
| Dec 31, 2024 | 1.56 Mn |
| Sep 30, 2024 | 7.75 Mn |
| Sep 30, 2024 | 7.75 Mn |
| Jun 30, 2024 | 17.82 Mn |
| Jun 30, 2024 | 17.82 Mn |
| Mar 31, 2024 | -5.87 Mn |
| Mar 31, 2024 | -5.87 Mn |
| Dec 31, 2023 | 4.24 Mn |
| Dec 31, 2023 | 4.24 Mn |